dc.contributor.advisor | Jamiruddin, Mohd Raeed | |
dc.contributor.author | Chowdhury, Shamima Zerin | |
dc.date.accessioned | 2022-09-26T05:29:25Z | |
dc.date.available | 2022-09-26T05:29:25Z | |
dc.date.copyright | 2022 | |
dc.date.issued | 2022-03 | |
dc.identifier.other | ID 17346018 | |
dc.identifier.uri | http://hdl.handle.net/10361/17304 | |
dc.description | This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022. | en_US |
dc.description | Cataloged from PDF version of thesis report. | |
dc.description | Includes bibliographical references (pages 94-105). | |
dc.description.abstract | Glioblastoma multiforme is one of the most dangerous primary brain tumors, with a poor prognosis even after vigorous treatment. Neurosurgical enhancements, the discovery of potent chemotherapeutic medicines, developments in radiation and innovations in targeted delivery have all contributed to an increase in the extension of survival in patients. This systematic review incorporates 12 clinical trials and presents a concise evaluation of studies where temozolomide, radiotherapy along with other drugs are used in collaboration to treat glioblastoma and efficacy outcomes, rate of tolerability, and patient life expectancy are recorded, investigated, and reviewed to discover which combination treatment leads to an extended survival time or minimal side effects in patients. High dose radiation and TMZ had the longest OS and PFS with moderate toxicity. (Temozolomide+ Radiation+ 06 Benzylguanine + Carmustine + Plerixafor) also had the longest median OS and the fewest adverse effects, indicating that the study was effective. Although it considerably increased patient survival, (TMZ+ radiation + TSC) had the lowest amount of toxicity. (Temozolomide+ irinotecan+ bevacizumab) showed the highest rate of side effects, despite having a good OS and PFS. | en_US |
dc.description.statementofresponsibility | Shamima Zerin Chowdhury | |
dc.format.extent | 113 pages | |
dc.language.iso | en | en_US |
dc.publisher | Brac University | en_US |
dc.rights | Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. | |
dc.subject | Temozolomide | en_US |
dc.subject | Radiotherapy | en_US |
dc.subject | Overall survival | en_US |
dc.subject | Progression-free survival | en_US |
dc.subject | Vascular endothelial growth factor receptor | en_US |
dc.subject.lcsh | Glioblastoma multiforme | |
dc.subject.lcsh | Gliomas | |
dc.title | A systematic review on the comparison of the safety and efficacy of temozolomide and radiotherapy along with another drug combination in the treatment of glioblastoma multiforme | en_US |
dc.type | Thesis | en_US |
dc.contributor.department | Department of Pharmacy, Brac University | |
dc.description.degree | B. Pharmacy | |